Table 2.
The distribution of FKBP5 rs1360780, BDNF rs6265, and NRN1 rs1475157 alleles in AD patients (n = 176) and the controls (n = 127), divided by low, medium, and high GSES outcomes
| GSES | Low | Medium | High | p | ||||
|---|---|---|---|---|---|---|---|---|
| n | % | n | % | n | % | |||
| BDNF rs6265 | ||||||||
| AD patients | C | 39 | 22.3 | 47 | 26.9 | 89 | 50.9 | 0.2271 |
| T | 17 | 28.8 | 14 | 23.7 | 28 | 47.5 | 0.3731 | |
| Controls | C | 10 | 8.1 | 114 | 91.9 | > 0.9991 | ||
| T | 2 | 6.1 | 31 | 93.9 | > 0.9991 | |||
| AD patients vs | C | 0.2601 | ||||||
| Controls | T | 0.7081 | 0.4352 | |||||
| FKBP5 rs1360780 | ||||||||
| AD patients | C | 39 | 23.5 | 43 | 25.9 | 84 | 50.6 | 0.5271 |
| T | 16 | 21.9 | 21 | 28.8 | 36 | 49.3 | 0.8722 | |
| Controls | C | 10 | 8.5 | 107 | 91.5 | > 0.9991 | ||
| T | 3 | 4.6 | 62 | 95.4 | 0.1991 | |||
| AD patients vs | C | > 0.9991 | 0.4232 | |||||
| Controls | T | 0.4941 | 0.074 | |||||
| NRN1 rs1475157 | ||||||||
| AD patients | A | 38 | 22.1 | 46 | 26.7 | 88 | 51.2 | 0.3451 |
| G | 10 | 21.3 | 14 | 29.8 | 23 | 48.9 | 0.8522 | |
| Controls | A | 10 | 7.9 | 117 | 92.1 | > 0.9991 | ||
| G | 2 | 5.6 | 34 | 94.4 | 0.7241 | |||
| AD patients vs | A | > 0.9991 | 0.6351 | |||||
| Controls | G | 0.708 | 0.6092 | |||||
p level of statistical significance with Bonferroni correction
GSES generalized self-efficacy scale, AD alcohol-dependent
1Fisher’s exact test
2Chi square test